KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Long-Term Debt Repayments (2019 - 2022)

Twist Bioscience (TWST) has disclosed Long-Term Debt Repayments for 4 consecutive years, with $3.1 million as the latest value for Q2 2022.

  • On a quarterly basis, Long-Term Debt Repayments rose 274.07% to $3.1 million in Q2 2022 year-over-year; TTM through Mar 2023 was $3.1 million, a 2785.19% increase, with the full-year FY2022 number at $1.6 million, down 53.26% from a year prior.
  • Long-Term Debt Repayments was $3.1 million for Q2 2022 at Twist Bioscience, up from -$11.6 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $10.0 million in Q4 2021 to a low of -$11.6 million in Q1 2022.
  • A 4-year average of $760846.2 and a median of $833000.0 in 2019 define the central range for Long-Term Debt Repayments.
  • Peak YoY movement for Long-Term Debt Repayments: surged 1300.48% in 2021, then crashed 562.32% in 2022.
  • Twist Bioscience's Long-Term Debt Repayments stood at $833000.0 in 2019, then crashed by 200.0% to -$833000.0 in 2020, then soared by 1300.48% to $10.0 million in 2021, then plummeted by 68.84% to $3.1 million in 2022.
  • Per Business Quant, the three most recent readings for TWST's Long-Term Debt Repayments are $3.1 million (Q2 2022), -$11.6 million (Q1 2022), and $10.0 million (Q4 2021).